Team Finds Markers of Inflammatory Breast Cancer in Blood

Why It Matters

A simple blood test could replace invasive tumor biopsies, accelerating IBC detection and enabling real‑time treatment decisions for a cancer subtype with the highest mortality rate.

Key Takeaways

• TGIRT sequencing captures complex RNAs missed by standard methods
• Blood samples show elevated noncoding RNAs and white blood cells in IBC
• Identified biomarkers enable liquid biopsy for early IBC detection
• Findings could accelerate targeted therapy development for aggressive breast cancer
• Study funded by NIH, Welch Foundation, BCRF, and Texas programs

Pulse Analysis

Inflammatory breast cancer (IBC) remains the most lethal breast cancer variant, largely because its aggressive nature hampers early detection and limits tissue access for molecular profiling. Traditional genomic approaches have struggled to separate IBC from non‑inflammatory forms, as their mutational landscapes overlap. The University of Texas team addressed this gap by deploying Thermostable Group II Intron Reverse Transcriptase (TGIRT) sequencing, a technique that tolerates extreme conditions and captures a broader spectrum of RNA species, including fragmented and non‑coding transcripts that standard enzymes overlook.

The TGIRT‑driven analysis revealed a distinct RNA signature in the blood of IBC patients: heightened levels of non‑coding RNAs, intron‑derived fragments, and a surge in white‑blood‑cell transcripts, indicating immune activation and splicing dysregulation. These biomarkers were absent or markedly lower in healthy donors and patients with other breast cancer subtypes. By translating these molecular clues into a liquid‑biopsy assay, clinicians could monitor disease progression and therapeutic response without the need for invasive tumor sampling, a critical advantage given the rapid spread and poor accessibility of IBC tumors.

Beyond diagnostics, the identified RNA markers open new avenues for targeted therapy development. Understanding the splicing abnormalities and immune signatures specific to IBC may guide the design of drugs that correct RNA processing or modulate the tumor‑associated immune environment. The study’s multi‑institutional funding—from NIH, the Welch Foundation, the Breast Cancer Research Foundation, and Texas state programs—underscores the strategic priority of translating such breakthroughs into clinical tools. As liquid‑biopsy technologies mature, IBC patients could benefit from earlier intervention, personalized treatment regimens, and improved survival outcomes.